KALY - CBD Drug Analyst Report Scheduled Next Week Adding Fuel To 400% Run Potential From $0.01 To $0.04
New York, NY -- August 22, 2019 -- InvestorsHub NewsWire -- via www.nextbigticker.com -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today released its up-to-date corporate financials reporting a 250% increase in revenue in the first six months of 2019 compared to the same period last year. The company attributed its $165,000 in YTD revenue and $70,000 profit to its new cannabis business launched after the acquisition of NCM Biotech in Q4 2018.
Earlier this week the company made a major CBD Drug announcement yesterday introducing its RespRx CBD Formulation for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). Tomorrow, the company plans to release more details on the patent application it filed on its RespRx drug and on the corresponding trademark application it filed when it launches a new website dedicated to RespRx.
KALY $0.01 Potential Run To $0.04
The company has experienced roughly $2 million in stock trading since first announcing its CBD Biopharmaceutical update. The PPS has seen over a 100% increase on very high volume and has been consolidating on still strong volume since the increase. The KALY PPS is solidly in the $0.01 ranging and looks like it could be basing for a run back to its almost $0.04 52-week high.
Other cannabis stocks making news today include Hemp Naturals, Inc. (HPMM) ,American Premium Water Corp (HIPH) and MC Endeavors, Inc. (MSMY)
NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.